The modified International Society of Urological Pathology system improves concordance between biopsy and prostatectomy tumour grade.
Gleason score
ISUP Grade Group
adenocarcinoma
biopsy
concordance
grading
prostate
upgrade
Journal
BJU international
ISSN: 1464-410X
Titre abrégé: BJU Int
Pays: England
ID NLM: 100886721
Informations de publication
Date de publication:
12 2021
12 2021
Historique:
pubmed:
27
7
2021
medline:
18
1
2022
entrez:
26
7
2021
Statut:
ppublish
Résumé
To assess the concordance between biopsy and radical prostatectomy (RP) specimens using the 2005 Gleason score (GS) and the International Society of Urological Pathology (ISUP) 2014/World Health Organization 2016 modified system, accounting for the introduction of transperineal biopsy and pre-biopsy multiparametric magnetic resonance imaging (mpMRI). Between 2002 and 2019, we identified 2431 patients with paired biopsy and RP histopathology from a prospectively recorded and maintained prostate cancer database. Biopsy specimens were graded according to the 2005 GS or ISUP 2014 modified system, according to the year of diagnosis. Multivariable logistic regression analysis was conducted to retrospectively assess the impact of prostate-specific antigen (PSA), PSA density, age, pre-biopsy mpMRI, and biopsy method, on the rate of upgraded disease. The kappa coefficient was used to establish the degree of change in concordance between groups. Overall, 24% of patients had upgraded disease and 8% of patients had downgraded disease when using the modified ISUP 2014 criteria. Agreement in the updated ISUP 2014 cohort was 68%, compared with 55% in the 2005 GS group, which was validated by a kappa coefficient that was good (k = 0.5 ± 0.4) and poor (k = 0.3 ± 0.1), respectively. In multivariable models, a change in grading system independently improved overall disease concordance (P = 0.02), and there were no other co-segregated patient or pathological factors such as PSA, total number of cores, maximum cancer length, biopsy route or the use of mpMRI that impacted this finding. The 2014 ISUP modifed system improves overall concordance between biopsy and surgical specimens, and thus allows more accurate prognostication and management in high-grade disease, independent of more extensive prostate sampling and the use of mpMRI.
Substances chimiques
Prostate-Specific Antigen
EC 3.4.21.77
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
45-51Informations de copyright
© 2021 The Authors BJU International © 2021 BJU International Published by John Wiley & Sons Ltd.
Références
Mottet N, Bellmunt J, Bolla M et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol 2017; 71: 618-29
Corcoran NM, Hong MKH, Casey RG et al. Upgrade in Gleason score between prostate biopsies and pathology following radical prostatectomy significantly impacts upon the risk of biochemical recurrence. BJU Int 2011; 108: E202-10
Cohen MS, Hanley RS, Kurteva T et al. Comparing the Gleason prostate biopsy and Gleason prostatectomy grading system: the Lahey Clinic Medical Center experience and an international meta-analysis. Eur Urol 2008; 54: 371-81
Alchin D, Murphy D, Lawrentschuk N. Risk factors for Gleason score upgrading following radical prostatectomy: a review of the current literature. Minerva Urol Nefrol 2017; 69: 459-65
Epstein J, Amin M, Reuter V, Humphrey P. Contemporary Gleason grading of prostatic carcinoma. Am J Surg Pathol 2017; 41: e1-7
Montironi R, Cheng L, Lopez-Beltran A et al. Original Gleason system versus 2005 ISUP modified Gleason system: the importance of indicating which system is used in the patient’s pathology and clinical reports. Eur Urol 2010; 58: 369-73
Offermann A, Hupe M, Sailer V, Merseburger A, Perner S. The new ISUP 2014/WHO 2016 prostate cancer grade group system: first résumé 5 years after introduction and systemic review of the literature. World J Urol 2019; 38: 657-62
Lee T, Ro J. Spectrum of cribriform proliferations of the prostate: from benign to malignant. Arch Pathol Lab Med 2018; 142: 938-46
Patel P, Wang S, Siddiqui M. The use of multiparametric magnetic resonance imaging (mpMRI) in the detection, evaluation, and surveillance of clinically significant prostate cancer (csPCa). Curr Urol Rep 2019; 20: 60
Epstein JI, Allsbrook WC, Amin MB, Egevad LL. The 2005 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma. Am J Surg Pathol 2005; 29: 1228-42
Scott S, Samaratunga H, Chabert C, Breckenridge M, Gianduzzo T. Is transperineal prostate biopsy more accurate than transrectal biopsy in determining final Gleason score and clinical risk category? A comparative analysis. BJU Int 2015; 116: 26-30
Epstein JI, Zelefsky MJ, Sjoberg DD et al. A contemporary prostate cancer grading system: a validated alternative to the Gleason score. Eur Urol 2016; 69: 428-35
De Nunzio C, Pastore AL, Lombardo R et al. The new Epstein Gleason score classification significantly reduces upgrading in prostate cancer patients. Eur J Surg Oncol 2018; 44: 835-9
Athanazio D, Gotto G, Shea-Budgell M, Yilmaz A, Trpkov K. Global Gleason grade groups in prostate cancer: concordance of biopsy and radical prostatectomy grades and predictors of upgrade and downgrade. Histopathology 2017; 70: 1098-106
Cowan T, Baker E, McCray G, Reeves F, Houlihan K, Johns-Putra L. Detection of clinically significant cancer in the anterior prostate by transperineal biopsy. BJU Int 2020; 126(Suppl 1): 33-7
Franklin A, Gianduzzo T, Yaxley J et al. Use of a trizonal schema to assess targeting accuracy in prostatic fusion biopsy. BJU Int 2020; 126(Suppl 1): 6-11
Scheltema MJ, Chang JI, Stricker PD et al. Diagnostic accuracy of 68 Ga-prostate-specific membrane antigen (PSMA) positron-emission tomography (PET) and multiparametric (mp)MRI to detect intermediate-grade intra-prostatic prostate cancer using whole-mount pathology: impact of the addition of 68 Ga-PSMA PET to mpMRI. BJU Int 2019; 124(Suppl 1): 42-9
Moussa A, Li J, Soriano M, Klein E, Dong F, Jones J. Prostate biopsy clinical and pathological variables that predict significant grading changes in patients with intermediate and high grade prostate cancer. BJU Int 2009; 103: 43-8
McNeal J, Yemoto C. Spread of adenocarcinoma within prostatic ducts and acini. Am J Surg Pathol 1996; 20: 802-14
Chen N, Zhou Q. The evolving Gleason grading system. Chin J Cancer Res 2016; 28: 58-64
Turan T, Gucluer B, Elifoglu O et al. The factors predicting upgrading of prostate cancer by using International Society for Urological Pathology (ISUP) 2014 Gleason grading system. Turk J Urol 2019; 45: 36-41
De Nunzio C, Simone G, Brassetti A et al. Metabolic syndrome is associated with advanced prostate cancer in patients treated with radical retropubic prostatectomy: results from a multicentre prospective study. BMC Cancer 2016; 16: 407
Lawrentschuk N. Urology trial success - get urologists involved early. BJU Int 2019; 124: 4
Donato P, Morton A, Yaxley J et al. Improved detection and reduced biopsies: the effect of a multiparametric magnetic resonance imaging-based triage prostate cancer pathway in a public teaching hospital. World J Urol 2019; 38: 371-9